Over 6.5 million AROA products have been used globally in a range of procedures to date, and the company has regulatory approval in 50 countries, including their main market, the
AROA’s products are based on its patented ECM technology, derived from the forestomach of sheep. The biomaterial contains over 150 proteins known to be important in the healing process and provides a scaffold, allowing healthy new tissue to develop.
Diabetic wounds to the feet commonly occur in patients with uncontrolled diabetes and are challenging to heal. A growing body of peer-reviewed clinical evidence shows that AROA’s advanced wound care products can be highly effective in treating diabetic ulcers, as referenced in this 2022 peer reviewed article published in The International Wound Journal.[i]
For the past two years, AROA has been donating their advanced wound care products to a charitable organization named Ãmanaki Foóu (Which means new hope in Tongan language) whose aim is to improve diabetes care for people in the pacific nation of
Ãmanaki Foóu relies on coordinated efforts of both US and Tongan based health providers who set aside time towards the yearly mission. But how did this all come about?
Dr.
In 2014,
Thus began a yearly mission to
The international wound care community is relatively small, so when the team at AROA became aware of the work of
“AROA is on a mission to unlock regenerative healing for everybody, so supporting this worthy cause, in our own backyard aligns with that”, says Dr.
Says Dr Tettelbach “If we just save one limb, it’s worth it. Studies show the 5-year mortality rate after a leg amputation is 50%, and in countries with less advanced healthcare systems, this can be closer to 80%.” says
On what keeps
[i] Bosque BA, Frampton C, Chaffin AE, Bohn GA, Woo K, DeLeonardis C, Lepow BD, Melin MM, Madu T, Dowling SG, May BCH. Retrospective real-world comparative effectiveness of ovine forestomach matrix and collagen/ORC in the treatment of diabetic foot ulcers. Int Wound J. 2022 May;19(4):741-753. doi: 10.1111/iwj.13670. |
About Aroa Biosurgery:
Aroa Biosurgery is a soft-tissue regeneration company committed to ‘unlocking regenerative healing for everybody’. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Over 6.5 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of
https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png
Source link
Investing.com